• Dual Luciferase Assay System: Reliable Reporter Data

  2026-09-03

  Learn how the Dual Luciferase Assay System, SKU K1136, can improve normalization and workflow control in mammalian reporter experiments linked to viability, proliferation, and cytotoxicity studies. This scenario-driven guide covers assay design, media compatibility, protocol parameters, interpretation, and practical product selection.

• p-Cresyl Sulfate: CKD Calcification Assay Guide

  2026-09-03

  Build reproducible chronic kidney disease models with p-Cresyl sulfate, from fresh-solution preparation to albumin-aware dose testing. The workflow connects endothelial dysfunction research with valvular interstitial cell calcification and klotho/SIRT1 pathway analysis.

• MDM1, p53, and Chemoradiotherapy Sensitivity in CRC

  2026-09-02

  The 2025 Cancer Biology & Medicine study identifies MDM1 as a regulator of colorectal cancer sensitivity to chemoradiotherapy through TP53 expression and apoptosis. Its combination of patient-derived expression evidence, genetic manipulation, transcriptomics, mechanistic assays, and xenograft testing supports MDM1 as a candidate predictive biomarker rather than merely a correlate of treatment response.

• MCT4 Loss, Ferroptosis, and Bladder Cancer

  2026-09-02

  The 2023 reference study identifies MCT4 loss as a metabolic trigger of ferroptotic stress in human bladder cancer 5637 cells, linking lactate transport to the AMPK/ACC pathway and autophagy suppression. Its combination of cell, molecular, redox, ultrastructural, and xenograft analyses provides a useful framework for testing whether MCT4-dependent metabolic remodeling can be exploited in bladder cancer research.

• Flumequine: Separating Arrest From Cell Death

  2026-09-01

  Flumequine is a DNA topoisomerase II inhibitor that can expose how enzyme perturbation changes proliferation and survival. This guide applies a dissertation-derived framework for separating growth arrest from cell killing in mechanistic assays.

• Veratridine for Sodium Channel Assay Design

  2026-09-01

  Veratridine converts sodium-channel inactivation into a controlled persistent-depolarization challenge for neuroscience, cardiac, and blocker-screening workflows. When paired with chamber-specific cardiomyocytes, it can help distinguish model identity from pharmacological response rather than treating all hPSC-derived cardiomyocytes as equivalent.

• Berberrubine, Urate Transporters, and JAK2/STAT3

  2026-08-31

  The reference study identifies berberrubine, a major berberine metabolite, as an anti-hyperuricemic agent that acts through both renal urate transport and inflammatory signaling. Its integrated mouse-model design connects reduced uric acid production, enhanced renal excretion, improved kidney pathology, and suppression of JAK2/STAT3-associated inflammation.

• GS967: A Causal Map of Late Sodium Signaling

  2026-08-31

  GS967 is a cardiac late sodium current inhibitor for separating pathological Na⁺ influx from broader electrophysiological effects. This article develops an assay-selection framework that connects Nav1.5 regulation, calcium loading, repolarization, relaxation, and arrhythmia phenotypes.

• Tamoxifen: Reliable Design for Cell Assays

  2026-08-30

  Learn how Tamoxifen (SKU B5965) can support reproducible viability, proliferation, cytotoxicity, and CreER-mediated gene knockout workflows. This scenario-based guide addresses mechanism, solvent handling, assay interpretation, and practical product-selection criteria without confusing biological activity with assay quality.

• Cell Counting Kit-8 for Hydrogel Cell Studies

  2026-08-29

  Use Cell Counting Kit-8 to quantify chondrocyte proliferation, viability, and biomaterial-associated cytotoxicity without a formazan solubilization step. This workflow translates a self-healing hyaluronic acid hydrogel study into practical assay design, controls, optimization checkpoints, and orthogonal validation.

• Tamoxifen in Mechanism-Driven Breast Cancer Research

  2026-08-28

  Tamoxifen is a selective estrogen receptor modulator with applications extending from endocrine biology to CreER-mediated gene knockout. This article presents an assay-centered framework connecting tamoxifen mechanism, experimental controls, and the emerging CARM1 research landscape.

• LncRNA MRF, FSHR, and BMSC Osteogenesis

  2026-08-28

  The 2025 study by Ning et al. identifies lncRNA MRF as a negative regulator of bone marrow mesenchymal stem cell osteogenesis and links its activity to FSHR-dependent cAMP-PKA-CREB signaling. Its combination of patient-derived observations, molecular perturbation, transcriptomics, pathway validation, and a mouse bone-defect model provides a mechanistic framework for studying impaired bone repair.

• KPT-330 Workflow for CRM1 Inhibition Studies

  2026-08-27

  KPT-330 (Selinexor) gives cancer researchers a practical way to connect CRM1-dependent nuclear export with apoptosis, cell-cycle control, and chemotherapy response. This workflow combines solid-tumor assays with a reference-guided DLBCL combination strategy to improve dosing, endpoint selection, and troubleshooting.

• ZNF263 and the Dual Luciferase Reporter Gene System

  2026-08-27

  A translational framework for using the Dual Luciferase Assay System to test how ZNF263 controls the ULK1 enhancer, autophagy, and intrahepatic cholangiocarcinoma proliferation while improving reporter assay rigor and scalability.

• NSC-23766 Rac GTPase Inhibitor Workflows

  2026-08-26

  NSC-23766 provides a practical way to interrogate Rac1 activation in cancer, endothelial-barrier, and metabolic assays. This guide connects dose planning, proximal Rac1 readouts, and troubleshooting with the newly described GPR81/FARP1/GLUT4 axis.

7979 records 1/532 page Next 12345 下5页 Last page